We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+16.48%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11.7B
AUM Growth
+$1.25B
Cap. Flow
-$79.9M
Cap. Flow %
-0.68%
Top 10 Hldgs %
34.47%
Holding
156
New
27
Increased
33
Reduced
24
Closed
20

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$208M
2
ACT.PRA
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
+$109M
3
BMY icon
Bristol-Myers Squibb
BMY
+$74.8M
4
BLUE
bluebird bio
BLUE
+$56.1M
5
CAH icon
Cardinal Health
CAH
+$54.7M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$191M
2
AGN
Allergan Inc
AGN
+$158M
3
MRK icon
Merck
MRK
+$149M
4
BIIB icon
Biogen
BIIB
+$113M
5
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$106M

Sector Composition

Rank Sector Weight
1 Healthcare 83.37%
2 Technology 0.15%
3 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
76
DELISTED
Sage Therapeutics
SAGE
$20.7M 0.18%
412,335
– –
MRGE
77
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
$20.7M 0.18%
4,628,500
– –
JAZZ icon
78
Jazz Pharmaceuticals
JAZZ
$16.1B
$19.9M 0.17%
115,000
– –
BAX icon
79
Baxter International
BAX
$12.7B
$19.6M 0.17%
+526,894
New +$20M
GWPH
80
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$18.4M 0.16%
+202,000
New +$16.4M
CNXR
81
DELISTED
Connecture, Inc.
CNXR
$18M 0.15%
1,740,000
+1,437,700
+476% +$13.3M
ASMB icon
82
Assembly Biosciences
ASMB
$497M
$17.9M 0.15%
+112,500
New +$15.2M
CLDX icon
83
Celldex Therapeutics
CLDX
$2.81B
$16.7M 0.14%
40,000
-97,480
-71% -$34.9M
XNCR icon
84
Xencor
XNCR
$1.44B
$16M 0.14%
1,044,615
-1,385
-0.1% -$21.9K
VRTX icon
85
Vertex Pharmaceuticals
VRTX
$125B
$15.9M 0.14%
135,000
-1,596,200
-92% -$191M
PCRX icon
86
Pacira BioSciences
PCRX
$1.04B
$15.6M 0.13%
176,000
– –
AMAG
87
DELISTED
AMAG Pharmaceuticals
AMAG
$15M 0.13%
275,000
-194,000
-41% -$9.25M
SGYP
88
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$14.4M 0.12%
+3,121,148
New +$10.1M
SLXP
89
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$14.2M 0.12%
82,000
– –
VTRS icon
90
PUT
Viatris
VTRS
$20.9B
$13.4M 0.11%
+225,000
New +$12.8M
SVA
91
DELISTED
Sinovac Biotech, Ltd
SVA
$13.2M 0.11%
2,667,500
-154,000
-5% -$759K
OSUR icon
92
OraSure Technologies
OSUR
$275M
$12.9M 0.11%
1,978,500
– –
IOVA icon
93
Iovance Biotherapeutics
IOVA
$2.02B
$12.1M 0.1%
+1,000,000
New +$11.3M
ASPX
94
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$11.9M 0.1%
118,600
+25,000
+27% +$1.67M
PBYI icon
95
CALL
Puma Biotechnology
PBYI
$398M
$11.8M 0.1%
+50,000
New +$10.7M
ADVM
96
DELISTED
Adverum Biotechnologies
ADVM
$11.5M 0.1%
+28,390
New +$12M
PTX
97
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$11.5M 0.1%
107,300
– –
ARQL
98
DELISTED
Arqule Inc
ARQL
$11M 0.09%
4,896,108
-805,892
-14% -$1.28M
CLLS
99
Cellectis
CLLS
$287M
$10.4M 0.09%
+300,000
New +$10.9M
ROKA
100
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$10.3M 0.09%
322,043
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q1 2015 Portfolio in Review

As of Q1 2015, OrbiMed held 156 positions worth $11.7B, up 12% from $10.5B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q1 2015 filing shows 27 new, 33 increased, 24 reduced and 20 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 104,200 shares worth $105M. The largest sale was Vertex Pharmaceuticals, an estimated $191M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 86% a quarter earlier, followed by Technology and Financials.

  • OrbiMed's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 104,200 shares worth $105M.
  • OrbiMed added most to Boston Scientific in Q1 2015, an estimated $208M increase.
  • OrbiMed's biggest Q1 2015 reduction was Vertex Pharmaceuticals, cutting an estimated $191M.
  • OrbiMed fully exited Allergan Inc in Q1 2015, selling an estimated $158M.
  • OrbiMed's ten largest holdings make up 34% of its $11.7B portfolio in Q1 2015.
  • OrbiMed opened 27 new positions and closed 20 in Q1 2015.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $11.7B.

Based on OrbiMed's 13F filing for Q1 2015, filed 15 May 2015.